Meeting
2013 ASCO Annual Meeting
Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies.
Authors
Gregory Lawrence Beatty
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA
Gregory Lawrence Beatty , Peter J. O'Dwyer , Jason Clark , Jack G Shi , Robert Charles Newton , Richard Schaub , Janet Maleski , Lance Leopold , Thomas Gajewski
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Immunotherapy and Biologic Therapy
Clinical Trial Registration Number
NCT01195311
Citation
J Clin Oncol 31, 2013 (suppl; abstr 3025)
DOI
10.1200/jco.2013.31.15_suppl.3025
Abstract #
3025
Poster Bd #
17
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase I, first-in-human, open-label, dose‑escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP‑1287 administered daily to patients with advanced solid tumors.
First Author: Ben George
Poster
2022 ASCO Annual Meeting
Phase I study of epacadostat in combination with sirolimus in advanced malignancy.
First Author: Chao Hui Huang
Poster
2020 ASCO Virtual Scientific Program
A phase I, dose-escalation and expansion study of TQ-B3139, a novel ALK TKI, in Chinese ALK or ROS1 positive advanced non-small cell lung cancer (NSCLC).
First Author: Yuxiang Ma
Poster
2018 ASCO Annual Meeting
A phase 1a / 1b first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP‑0903, a potent inhibitor of AXL kinase, administered daily for 21 days to patients with advanced solid tumors.
First Author: John Sarantopoulos